Interleukin-2 therapy in HIV infection

AIDS Patient Care and STDs

Volumn 12, Issue 3, 1998, Pages 187-197

  Pahwa, Savita ^a,b   Morales, Maripaz ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Division of Allergy/Immunology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; DIDANOSINE; INDINAVIR; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; NUCLEOSIDE ANALOG; RECOMBINANT INTERLEUKIN 2; THALIDOMIDE; THYMOSIN ALPHA1; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; ZALCITABINE; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRADERMAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOCYTE COUNT; MAXIMUM PERMISSIBLE DOSE; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

EID: 0031920282     PISSN: 10872914     EISSN: None     Source Type: Journal    
DOI: 10.1089/apc.1998.12.187     Document Type: Review

References (14)

1. Emergy S, Lane HC. Immune-based therapies in HIV infection: recent developments. AIDS 1996;10: (suppl)159-163.
2. Smith KA. dose IL-2 Immunotherapy. Blood 1993;81:1414-1423.
3. Taniguchi T, Matsui H, Hamuro J. Structure and human expression of a cloned DNA for IL-2. Nature 1983;302:305-310.
4. Kovacs J, Baseler M, Dewar RJ, et al. Increases in CD4 T lymphocytes with intermittent course of Interleukin-2 in patients with human immunodeficiency virus infection. N Engl J Med 1995;332:567-575.
5. Jacobson EL, Pilaro FG, Smith KA. Rational IL-2 therapy for HIV positive individuals: daily low doses enhance immune function without toxicity. Proc Natl Acad Sci USA 1996;93:10405-10410.
6. Smith KA. Interleukin-2: inception, impact and implications. Science 1988;240:1169-1176.
7. Kovacs J, Vogel S, Lane HC, et al. Controlled trial of interleukin 2 infusions in patients infected with the human immunodeficiency virus. N Engl J Med 1996;35:1350-1356.
8. Carr A, Lloyd A, Emery S, et al. A randomized, controlled trial of rhIL-2 or polyethylene glycol rhIL-2 (PEG IL-2) plus antiretroviral therapy (AR) versus AR alone in HIV infected patients with 200-500 CD4+ cells. XI International Conf AIDS, Vancouver BC, 1996, Abstract We. B.292.
9. Falloon J, Owens C, MK 639 with IL-2 in HIV. 35th Interscience Conference on Antimicrobial agents and chemotherapy. San Francisco, September 1995 (Abstract 1-176).
10. Davey RJ, Chaitt D, Piscitelli SC, et al. Subcutaneous administration of interleukin 2 in HIV type 1-infected persons. J Infect Dis 1997;175:781-789.
11. AIDS Clinical Trials Information Database. http://www.actis.org.
12. Davery RT, Chaitt D, Kovacs J, et al. XIth Internationl Conference on AIDS, Abstract 2305, Vancouver, Canada, July 7-12, 1996.
13. Teppler H, Kaplan G, Smith KA, Montana AL, Meyn P, Cohn ZA. Prolonged immunostimulatory effect of low dose PEG-IL-2 in patients with HIV type 1 infection. J Exp Med 1993;177:483-492.
14. Schwartz DH, Skowron G, Merigan TC. Safety and effects of IL-2 plus zidovudine in asymptomatic individuals infected with HIV. J AIDS 1991;4:11-23.